Please login to the form below

Not currently logged in
Email:
Password:

drug safety

This page shows the latest drug safety news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor

The FLIGHT-FXR study assessed the safety, tolerability and efficacy of the drug in NASH patients. ... Among these was hepatic fat fraction, alanine aminotransferase (an enzyme which signals liver damage) and body weight, as well as a favourable safety

Latest news

  • Arbutus hit hard as new hep B drug fails on safety Arbutus hit hard as new hep B drug fails on safety

    It has since abandoned the programme in favour of follow-up RNAi drug AB-729, while another candidate – RNA destabiliser AB-452 – has been delayed by safety concerns. ... in time – a fairly sizeable minority develops chronic HBV that resists drug

  • Biogen loses another pipeline drug to toxicity concerns Biogen loses another pipeline drug to toxicity concerns

    Follows discontinuation of Eisai-partnered Alzheimer's drug. Just a few days after calling time on its Eisai-partnered Alzheimer’s drug  elenbecestat, Biogen has another pipeline casualty – this time its ... The decision – announced in an  update

  • Biogen and Eisai drop Alzheimer’s drug elenbecestat Biogen and Eisai drop Alzheimer’s drug elenbecestat

    Data Safety Monitory Board suggested the drug had an “unfavourable risk-benefit ratio”. . ... However, there was concern that patients on lower dose of the drug seemed to decline more quickly than those on the placebo arm.

  • TMC’s full data for inclisiran impresses at ESC TMC’s full data for inclisiran impresses at ESC

    The safety of the drug compared to placebo was also similar, with patients treated with placebo or inclisiran experiencing a similar level of at least one serious treatment emergent adverse event ... TMC licensed the rights to inclisiran from Alnylam

  • FDA rejects Sarepta’s new Duchenne drug over safety fears FDA rejects Sarepta’s new Duchenne drug over safety fears

    Sarepta gained approval for Exondys 51 three years ago amid controversy about its lack of robust efficacy data, but the drug is now established and creating a market for follow-on ... Using a similar mechanism, this drug skips exon 45, and analysts

More from news
Approximately 3 fully matching, plus 403 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Patient safety drive. For John Haanen, demands for safer immunotherapies are also a factor in the FDA’s call for biomarker and assay harmonisation. ... The potential downside, Magid Diefenbach said, is that immunotherapy firms may focus drug

  • Real-world studies Real-world studies

    myriad of information, from safety monitoring and drug utilisation studies of marketed products in the EU to routine safety monitoring of marketed products and filling evidentiary gaps for particular rare diseases ... trial recruitment, support

  • Streamlining clinical trials – why better data use is key Streamlining clinical trials – why better data use is key

    Compliance requirements are in place to ensure patient safety when a drug ultimately comes to market. ... endpoints and patient safety, which can lead to better data, faster enrolment and reduced patient burdens.”.

  • Five questions guiding the way to actual patient-centricity Five questions guiding the way to actual patient-centricity

    We also learned that patients’ trust, encouraged by a better comprehension of our work, has been correlated with better clinical outcomes and features, including drug adherence and reporting of safety concerns. ... 3 Are we ready to offer value (beyond

  • Behaviour change – a missing ingredient? Behaviour change – a missing ingredient?

    It already invests hugely in long-term development programmes to understand drug efficacy and safety; the step required to take the same long-term view on implementing behaviour change programmes is ... If behavioural aspects are investigated and

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics